Literature DB >> 15225726

Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS.

Miho Yamaguchi1, Yayoi Miyashita, Yumi Kumagai, Shosuke Kojo.   

Abstract

In fulminant hepatic failure, various toxins causing multi-organ failure increase in plasma. As a novel toxin, ceramide, a well-studied lipid mediator of apoptosis, levels were determined by LC-MS/MS in the liver and plasma of D-galactosamine-intoxicated rats. 18 and 24h after intraperitoneal administration of D-galactosamine (1g/kg body weight) to rats, fulminant hepatic failure occurred as evidenced by a severe elevation in plasma GOT and GPT. The liver concentration of minor ceramide components (C18:0, C20:0, C22:1, C22:0, and C24:2) increased significantly compared to that in the control group that was given saline. The plasma concentration of major ceramides (C24:0, C24:1, C16:0, C22:0, C22:1, and C18:0) increased 24h after administration of D-galactosamine and the total ceramide concentration was also increased to 3.6 times that in the control. In conclusion, the increased concentrations of ceramides in plasma during fulminant hepatic failure may be one of important toxins causing damage in other organs including the brain and kidney.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225726     DOI: 10.1016/j.bmcl.2004.05.046

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry.

Authors:  Takhar Kasumov; Hazel Huang; Yoon-Mi Chung; Renliang Zhang; Arthur J McCullough; John P Kirwan
Journal:  Anal Biochem       Date:  2010-02-21       Impact factor: 3.365

2.  Association of ceramides in human plasma with risk factors of atherosclerosis.

Authors:  Ikuyo Ichi; Kayoko Nakahara; Yayoi Miyashita; Atsuko Hidaka; Sahoko Kutsukake; Kana Inoue; Taro Maruyama; Yoshikazu Miwa; Mariko Harada-Shiba; Motoo Tsushima; Shosuke Kojo
Journal:  Lipids       Date:  2006-09       Impact factor: 1.646

3.  A hierarchical approach employing metabolic and gene expression profiles to identify the pathways that confer cytotoxicity in HepG2 cells.

Authors:  Zheng Li; Shireesh Srivastava; Xuerui Yang; Sheenu Mittal; Paul Norton; James Resau; Brian Haab; Christina Chan
Journal:  BMC Syst Biol       Date:  2007-05-11

4.  Very Long-Chain C24:1 Ceramide Is Increased in Serum Extracellular Vesicles with Aging and Can Induce Senescence in Bone-Derived Mesenchymal Stem Cells.

Authors:  Andrew Khayrullin; Priyanka Krishnan; Luis Martinez-Nater; Bharati Mendhe; Sadanand Fulzele; Yutao Liu; Julie A Mattison; Mark W Hamrick
Journal:  Cells       Date:  2019-01-10       Impact factor: 6.600

5.  Plasma ceramides target skeletal muscle in type 2 diabetes.

Authors:  John P Kirwan
Journal:  Diabetes       Date:  2013-02       Impact factor: 9.461

6.  Elevated ceramides 18:0 and 24:1 with aging are associated with hip fracture risk through increased bone resorption.

Authors:  Beom-Jun Kim; Jin Young Lee; So Jeong Park; Seung Hum Lee; Su Jung Kim; Hyun Ju Yoo; Sarah I Rivera De Pena; Meghan McGee-Lawrence; Carlos M Isales; Jung-Min Koh; Mark W Hamrick
Journal:  Aging (Albany NY)       Date:  2019-11-01       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.